CAPNIA

About CAPNIA

Capnia, through its CoSense® ETCOc Monitor, offers a non-invasive, bedside breath test designed to identify hemolysis and neurotoxic risks in neonates by detecting rising unconjugated bilirubin levels. This technology aims to prevent conditions such as hemolytic hyperbilirubinemia and Kernicterus. The CoSense® monitor is grounded in extensive research and supported by peer-reviewed studies and endorsements from neonatology experts. It revolutionizes neonatal care by enabling precise, customized interventions, including vigilant monitoring and effective phototherapy. Capnia serves the neonatal healthcare market, providing hospitals and healthcare providers with advanced tools to improve patient outcomes. The business model focuses on selling and supporting the CoSense® monitors, generating revenue through product sales and potentially through service agreements for ongoing support and maintenance.